Ranbaxy gets hit by FDA again

Ranbaxy_Logo.svgRanbaxy stock took a 30% hit today following an import alert issued by the FDA. The alert was reportedly issued based on serious cGMP issues at the Mohali plant from September and December 2012 483s. ┬áRanbaxy’s other two plants in India were already barred from importing to the U.S., this third plant in India was supposed to be the model plant, paving the way to a recovery. Obviously, this is a huge blow to the company.

For more context on Ranbaxy’s tumultuous year, read FiercePharmaManufacturing’s write-up. ┬áFDAzilla has the September 2012 FDA 483 available for immediate purchase and download in the FDAzilla store.

 

 

What do you think?